Clinical Report: MIAT: A Key Long Non-Coding RNA Influencing Cardiovascular and Cerebrovascular Disorders
Overview
This review highlights the role of Myocardial infarction-associated transcript (MIAT) in cardiovascular and cerebrovascular diseases. It integrates recent research findings and discusses challenges for clinical application.
Background
Cardiovascular and cerebrovascular diseases are leading causes of mortality globally, necessitating ongoing research into their underlying mechanisms. Long non-coding RNAs, such as MIAT, have emerged as significant regulators of gene expression and may influence various pathological processes.
Data Highlights
No numerical data or trial data is provided in the source material.
Key Findings
MIAT is implicated in multiple diseases beyond myocardial infarction, including ischemic stroke and various cancers.
Genome-wide association studies have linked MIAT single nucleotide polymorphisms to myocardial infarction incidence.
MIAT exhibits dynamic subcellular localization that is cell-type dependent and context-specific.
There are currently no clinical trials targeting MIAT, but its aberrant expression in diseases suggests potential for future research.
This review synthesizes literature up to 2025, focusing on MIAT's roles in both cardiovascular and cerebrovascular diseases.
Clinical Implications
Further research is needed to explore MIAT's clinical applications and address challenges in translation.
Conclusion
This review provides a comprehensive analysis of MIAT's role in cardiovascular and cerebrovascular disorders.
